Topo II inhibitor,immunosuppresive antineoplastic antibiotic
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
Quality Control & MSDS
- View current batch:
Related Biological Data
|Description||Doxorubicin (Adriamycin) is an antibiotic agent, inhibitor of DNA topoisomerase II and inducer of DNA damage and apoptosis.|
|Cas No.||23214-92-8||SDF||Download SDF|
|Synonyms||Adriamycin, Doxil, Adriablastin, Doxorubicinum, Myocet|
|Solubility||Soluble in DMSO||Storage||Store at RT|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
Doxorubicin down-regulates HDAC1 expression and up-regulates miR-520h to induce DNA damage in cancer cells.
Doxorubicin is an anti-neoplastic agent with cardiotoxicity.
GC7 enhanced doxorubicin cytotoxicity and inhibited doxorubicin-induced EMT in epithelial HCC cells.
Doxorubicin enhanced tumor infiltration by IFN-γ-secreting Tcells and decreased the content of TAMs in MMTV-neu mice.
Although a few factors, including body composition, age, gender, changes in monocyte count and repeated dosing, have impacts on pharmacokinetic properties of PLD, clinical risk factors of ovarian cancer patients who have PPE and receive PLD are rarely identified.
Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture.  It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.
Doxorubicin intercalates into DNA double strand and inhibits the progression of DNA topoisomerase II, stopping replication process.  Doxorubicin also induces histone eviction from open chromatin, causing DNA damage and epigenetic deregulation. 
Doxorubicin is administrated intravenously. Approximately 75% of doxorubicin and its metabolites bind to plasma protein. Doxorubicin does not cross blood brain barrier. 50% of the drug is eliminated unchanged from the body mainly though bile excretion. The remaining undergoes one-electron reduction, two-electron reduction, and deglycosidation. The major metabolite is a potent membrane ion pump inhibitor, which is associated with cardiomyopathy. 
Brayfield, A, ed. (2013). Doxorubicin. Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
Pommier Y., et al. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology 17 (5): 421–433.
Pang, B., et al. (2013). Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 4 (5): 1908
Boucek RJ., et al. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J of Biol Chem 262: 15851-15856.